Home › Funds › Vestal Point Capital, LP › GLUE
Vestal Point Capital, LP position in GLUE
MONTE ROSA THERAPEUTICS INC · Health Care
Vestal Point Capital, LP reported holding 4,600,000 shares of GLUE (MONTE ROSA THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$111.3M, representing 2.60% of its reported portfolio and ranking #13 among its reported holdings. Vestal Point Capital, LP has disclosed GLUE holdings in 7 of the last 9 reported quarters, going back to Q2 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Vestal Point Capital, LP's GLUE position evolved
Vestal Point Capital, LP first disclosed a stake in GLUE in Q2 2024 at 890,000 shares (US$3.3M). The position peaked in Q2 2026 at 4,600,000 shares, worth US$111.3M. Across 7 filings, Vestal Point Capital, LP increased the stake 3 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 4,600,000 shares valued at US$111.3M — an increase of 996,535 shares quarter over quarter.. Notable position changes include a 54% trim in Q4 2024 (shares fell 33% over the following quarter), a 365% increase in Q1 2026 (shares rose 47% over the following quarter), a 28% increase in Q2 2026 (shares fell 51% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 890.00K | $3.33M | New |
| Q3 2024 | 930.00K | $4.93M | Add |
| Q4 2024 | 425.00K | $2.95M | Reduce |
| Q3 2025 | 800.00K | $5.93M | New |
| Q4 2025 | 775.00K | $12.15M | Reduce |
| Q1 2026 | 3.60M | $59.28M | Add |
| Q2 2026 | 4.60M | $111.32M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GLUE and 13F data
GLUE (MONTE ROSA THERAPEUTICS INC) is a Health Care company. 73 other funds we track also report a position in GLUE — the largest reported positions include NEA Management Company, LLC (US$186.2M), TCG Crossover Management, LLC (US$111.9M), BVF INC/IL (US$108.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GLUE
- NEA Management Company, LLC 7.69M sh · $186.15M · Q2 2026
- TCG Crossover Management, LLC 4.62M sh · $111.86M · Q2 2026
- BVF INC/IL 4.46M sh · $107.95M · Q2 2026
- BAKER BROS. ADVISORS LP 4.35M sh · $105.17M · Q2 2026
- MONTANOVA CAPITAL, LLC 3.55M sh · $85.90M · Q2 2026
- Versant Venture Management, LLC 3.18M sh · $76.97M · Q2 2026
- BRAIDWELL LP 2.45M sh · $59.33M · Q2 2026
- Aisling Capital Management LP 1.56M sh · $37.65M · Q2 2026
- Bellevue Group AG 1.19M sh · $28.80M · Q2 2026
- MPM BioImpact LLC 1.16M sh · $28.10M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.00M sh · $24.20M · Q2 2026
- Nextech Invest Ltd. 761.15K sh · $18.42M · Q2 2026
More on Vestal Point Capital, LP
FAQ
How long has Vestal Point Capital, LP held GLUE?
Vestal Point Capital, LP has disclosed GLUE holdings in 7 of the last 9 reported quarters, going back to Q2 2024.
What is Vestal Point Capital, LP's current position in GLUE?
As of Q2 2026, Vestal Point Capital, LP holds 4.60M shares of GLUE (MONTE ROSA THERAPEUTICS INC), valued at $111.32M, representing 2.60% of its reported portfolio and ranking #13.
Has Vestal Point Capital, LP been buying or selling GLUE?
In the latest 13F filing (Q2 2026), Vestal Point Capital, LP increased its position in GLUE. The position peaked in Q2 2026 at 4.60M shares.
Which other funds hold GLUE?
Other major institutional holders of GLUE include NEA Management Company, LLC, TCG Crossover Management, LLC, BVF INC/IL, among 73 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.